DocWire News Editors

DocwireNews

According to 52-week study results presented at the annual meeting, subcutaneous secukinumab (SEC) provided sustained inhibition of radiographic progression in patients with active psoriatic arthritis. The phase III study, led by Philip J. Mease, MD, of the University of Washington in Seattle, also found sustained or improved clinical responses, as well as a safety profile consistent with previous reports.SEC is a fully human monoclonal IgG1 antibody that selectively targets interleukin-17A. In the FUTURE 5 study, the treatment significantly improved signs and symptoms of PsA and inhibited radiographic progression versus placebo at week 24. At the 2018 annual conference of American College of Rheumatology/Association of Rheumatology Health Professionals, the team reported on radiographic progression, additional efficacy endpoints, and safety through 52 weeks.The researchers randomized 996 patients with active PsA into four groups: subcutaneous (SC) SEC 300 mg with loading dosage (LD) (n = 222), SC SEC 150 mg with LD (n = 220), 150 mg SC SEC without LD (n = 222), or placebo (n = 332). All patients received SEC or placebo at baseline and at weeks 1, 2, 3, and 4, then every 4 weeks. Patients in the placebo group were switched to SEC 300 mg or 150 mg at week 16 or 24.To determine radiographic progression, two blinded researchers (plus adjudicator if necessary) assessed mean changes in van der Heijde&ndash;modified total Sharp score for PsA, based on hand/wrist/foot radiographs obtained at baseline and weeks 16, 24, and 52. In addition, researchers considered American College of Rheumatology 20/50 Criteria, Psoriasis Area and Severity Index 75 score, and whether dactylitis and enthesitis resolved.About 90% of patients completed 52 weeks of treatment, and inhibition of radiographic progression was sustained through 52 weeks. Clinical responses also were sustained or improved through 52 weeks. Exposure-adjusted incidence rates of selected AEs were serious infections (1.6),&nbsp;Candida&nbsp;infections (2.2), Crohn&rsquo;s disease (0.2), ulcerative colitis (0.1), major adverse cardiovascular event (0.2), and malignant/unspecified tumors (0.5). Therefore, the safety profile in this study was similar to results previously reported.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study[690]

ACR 2018 Conference

According to 52-week study results presented at the annual meeting, subcutaneous secukinumab (SEC) provided sustained inhibition of radiographic progression in patients with ...

Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe